clinical dataZEUS failure clouds future of Novo’s cardiovascular plansNovo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales. more ➔
licensingPharmanovia licenses China-approved PARP drug for up to €423.5MUK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million. more ➔
artificial intelligenceRelation deepens GSK alliance with $110M dealLondon-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to … more ➔
clinical dataSanofi axes two more inflammatory-disease drugsSanofi has discontinued development of itepekimab and balinatunfib after disappointing clinical results, ending ongoing programmes across respiratory and inflammatory diseases. more ➔
RegulatoryCHMP backs first CETP inhibitor after two decades of failureOn July 23, Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended the CETP inhibitor obicetrapib for approval after a string of big-name Phase 3 failures over the past two decades. … more ➔
financeGSK announces plan to axe UK Stevenage R&D hub, moving to CambridgeGSK has announced plans to shut its UK R&D headquarters in Stevenage, UK, moving operations north to a new site in Cambridge, while also announcing a company-wide programme to reduce annual costs by … more ➔
fundraisingPentixapharm raises €20.4M for Phase 3 diagnostic trialBerlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline. more ➔
licensingChiesi retreats from Gossamer PAH programme after Phase 3 missItalian pharmaceutical group Chiesi has returned all development and commercial rights to seralutinib to Gossamer Bio, ending a pulmonary arterial hypertension partnership originally valued at up to … more ➔
RegulatoryFast-track trial approval: a way to jump the EU queue?Launched in 2022, the EU Clinical Trials Information System (CTIS) aims to streamline and centralise the process of applying for clinical trial authorisation, but has also increased typical approval … more ➔
M&Aargenx pays $2.2B for Forte’s early autoimmune promiseBelgian-Dutch immunology company argenx has agreed to acquire Forte Biosciences for $2.2 billion (€1.9 billion), gaining FB102, an early-stage antibody that has already produced efficacy signals in … more ➔
